Comparison Between Roche Integra 400 Plus and Abbott Architect Ci8200 in Alanine Aminotransferase Assay

Overview

Journal Pract Lab Med

Specialty Biochemistry

Date 2019 Apr 24

PMID 31011608

Citations 1

Authors

Somiya Lamrabat

Amina Lyagoubi

Ouardia Bouayadi

Jalila Elmalki

Khadija Elkouche

Mohammed Bensalah

Mohammed Choukri

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this work is to present the results of a comparative study between the ALT assay on Integra 400 plus Roche Diagnostic versus Architect ci8200 of Abbott Diagnostic.

Methods: A total of 200 patients hospitalized in the various departments of the university hospital Mohammed VI of Oujda were prospectively tested on two systems: Abbott Architect ci8200 and Roche Integra 400 plus. Both analyzers use the spectrophotometric technique by coupling the transamination reaction to the oxidation-reduction reaction at NAD. The agreement of the results between the different techniques was evaluated using the Bland-Altman difference diagram and the Passing-Bablok and Deming regression line.

Results: There was a high concordance between the two assays: the equation of the Passing-Bablok line is YArchitect = -0,5625 + 0,9917 XIntegra with a correlation coefficient r = 0.999. The Bland-Altman diagram shows that the mean bias between the two methods is of the order of 1.1 IU/L and the difference between the ALT measurements by Architect and Integra is in the range of -1.4 to 3.6.

Conclusion: Our study shows a high correlation of the ALT assay results between the architect ci8200 and Integra 400 plus.

Citing Articles

Performance evaluation of QuantStudio 1 plus real-time PCR instrument for clinical laboratory analysis: A proof-of-concept study.

Wang Z, Yi J, Yu Q, Liu Y, Zhang R, Zhang D Pract Lab Med. 2023; 36:e00330.

PMID: 37649547 PMC: 10462677. DOI: 10.1016/j.plabm.2023.e00330.

References

Lawlor D, Sattar N, Davey Smith G, Ebrahim S . The associations of physical activity and adiposity with alanine aminotransferase and gamma-glutamyltransferase. Am J Epidemiol. 2005; 161(11):1081-8. DOI: 10.1093/aje/kwi125. View

Fraser A, Ebrahim S, Davey Smith G, Lawlor D . A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology. 2007; 46(1):158-65. DOI: 10.1002/hep.21667. View

Goessling W, Massaro J, Vasan R, DAgostino Sr R, Ellison R, Fox C . Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008; 135(6):1935-44, 1944.e1. PMC: 3039001. DOI: 10.1053/j.gastro.2008.09.018. View

Ruhl C, Everhart J . Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2008; 136(2):477-85.e11. DOI: 10.1053/j.gastro.2008.10.052. View

Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor D . Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care. 2009; 32(4):741-50. PMC: 2660465. DOI: 10.2337/dc08-1870. View

Siddiqui M, Sterling R, Luketic V, Puri P, Stravitz R, Bouneva I . Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology. 2013; 145(6):1271-9.e1-3. PMC: 3840068. DOI: 10.1053/j.gastro.2013.08.036. View

Kunutsor S, Apekey T, Seddoh D, Walley J . Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014; 43(1):187-201. DOI: 10.1093/ije/dyt192. View

Kunutsor S, Seddoh D . Alanine aminotransferase and risk of the metabolic syndrome: a linear dose-response relationship. PLoS One. 2014; 9(4):e96068. PMC: 4004562. DOI: 10.1371/journal.pone.0096068. View

Kunutsor S, Apekey T, Khan H . Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 2014; 236(1):7-17. DOI: 10.1016/j.atherosclerosis.2014.06.006. View

10.

Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P . Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015; 47(3):181-90. DOI: 10.1016/j.dld.2014.09.020. View

11.

Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F . Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015; 31(5):936-44. DOI: 10.1111/jgh.13264. View

12.

Bland J, Altman D . Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1(8476):307-10. View

13.

Bablok W, Passing H, Bender R, Schneider B . A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem. 1988; 26(11):783-90. DOI: 10.1515/cclm.1988.26.11.783. View